Top Medical News
Jairia Dela Cruz, 14 hours ago
The novel vasopressin 1b (V1b) receptor antagonist ABT-436 shows potential in the treatment of alcohol use disorder (AUD), effectively reducing the frequency of drinking but without significantly altering the amount consumed, according to the results of a multisite phase II trial.
Angiotensin receptor blockers (ARBs) appear to provide better protection against cardiovascular (CV) events compared with ACE inhibitors (ACEIs) in patients with established CV disease, according to a study.
Jairia Dela Cruz, Yesterday
Use of phosphodiesterase-5 (PDE5) inhibitors following a first myocardial infarction (MI) may reduce the risk of long-term adverse outcomes, including mortality and heart failure hospitalization, in a dose-dependent fashion, according to a Swedish study.
Patients often seek consultation at the pharmacy for superficial skin infection. The goal of this activity is to improve pharmacists' knowledge on strategies to manage bacterial skin infection.
Please click here to access this module
Cigarette cravings can make or break a smoker’s chance of quitting succesfully. The goal of this activity is to improve pharmacists’ knowledge on cravings and strategies to help quitters manage them.
Please click here to access the module. 
There are frequent occurrences of anti-infliximab (IFX) antibodies at any time during IFX treatment, according to a recent study. Anti-IFX antibodies are associated with younger age at IFX initiation, infusion reactions and arthritis as treatment indication.
Saras Ramiya, 2 days ago
Women can now gently and precisely trim their delicate areas such as the eyebrows, underarms and bikini lines using a new gadget.
Special Reports
13 Mar 2017
With the drive to share the current healthcare expert’s practices in managing different types of infections, Mundipharma conducted its 1st PLUS (Pharmacy cLinical UpdateS) Summit by inviting a group of consultants to share the role of povidone-iodine (PVP-I) in infection prevention and management with the community pharmacists on 15th–16th October 2016 in Port Dickson.
Roshini Claire Anthony, 24 Jan 2017

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, was associated with a reduced rate of disability progression in individuals with primary progressive multiple sclerosis (MS), based on findings of the phase III ORATORIO* trial.

16 Dec 2016
KEYTRUDA – Pembrolizumab 100 mg/4 mL soln for inj – Merck Sharp & Dohme
16 Dec 2016
BASALOG – Insulin glargine (rDNA) 100 IU/mL soln for inj (cartridge) – CCM Pharmaceuticals
16 Dec 2016
INVOKANA – Canagliflozin hemihydrate 100 mg and 300 mg FC tab – Johnson & Johnson (Janssen)
16 Dec 2016
ESMYA – Ulipristal acetate 5 mg tab – Zuellig Pharma
Prof. Abdul Rashid, Prof. Martin Strauss, Prof. Alistair Hall, 12 Dec 2016
Hypertension is a leading cause of mortality globally and is of particular concern in the Asia Pacific region where there are more deaths due to poor blood pressure (BP) control than in any other region in the world. At a recent Servier-sponsored satellite symposium held during the ASEAN Federation of Cardiology Congress in Yangon, Myanmar, Professor Abdul Rashid, An Nur Specialist Hospital, Selangor, Malaysia, discussed the challenges associated with managing hypertension in the region. In addition, Professor Martin Strauss, North York General Hospital, Toronto, Canada and Professor Alistair Hall, Leeds General Infirmary, UK, discussed the different effects of angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) on cardiovascular (CV) outcomes, highlighting the additional protection against myocardial infarction (MI) offered by ACE inhibitors such as perindopril.
Conference Reports
Roshini Claire Anthony, 21 Mar 2017

Prophylactic infusion of levosimendan did not reduce death or perioperative myocardial infarction or the need for dialysis or mechanical cardiac assist device more than placebo in patients at risk for low cardiac output syndrome undergoing cardiac bypass. However, it increased cardiac output and reduced low cardiac output syndrome, according to primary findings of the LEVO-CTS* trial. 

Pearl Toh, 21 Mar 2017
Intensive LDL lowering through the addition of the PCSK9* inhibitor evolocumab to statin therapy significantly reduced the risk of cardiovascular (CV) events in patients with existing atherosclerotic CV disease, according to data from the FOURIER** trial presented at the American College of Cardiology’s 66th Annual Scientific Session (ACC.17) held in Washington, DC, US.
Pearl Toh, 13 Mar 2017
Pearl Toh finds out from Professor Anna Lok, director of clinical hepatology at the University of Michigan in Ann Arbor, Michigan, US, on integrating guidelines, research data, and clinical setting in decision making for management of hepatitis B during the recent Asian Pacific Association for the Study of the Liver Annual Meeting held in Shanghai, China.

Pearl Toh, 12 Mar 2017
Add-on of pegylated interferon (pegIFN) to nucleos(t)ide analogues (NA) therapy may be a better strategy than a switch from NA to pegIFN in patients with chronic hepatitis B (CHB) who are on long-term NA therapy, according to data from an interim analysis of the SWAP* study presented at the recent Asian Pacific Association for the Study of the Liver Annual Meeting (APASL 2017) held in Shanghai, China.
Pearl Toh, 10 Mar 2017
Contact aspiration is comparable to stent retriever (SR) as frontline thrombectomy for patients with acute ischaemic stroke resulting from large vessel occlusion (LVO), according to the ASTER* trial presented at the recent International Stroke Conference (ISC 2017) held in Texas, Houston, US.
Roshini Claire Anthony, 09 Mar 2017

The phosphodiesterase 3 inhibitor cilostazol may prevent secondary stroke in individuals with a recent history of ischaemic stroke. However, there was a higher incidence of myocardial infarction in this group, according to findings of the PICASSO* study presented at the International Stroke Conference 2017 (ISC 2017) in Houston, Texas, US.

Roshini Claire Anthony, 08 Mar 2017

Initiating statin therapy within 24 hours of hospitalization for an acute ischaemic stroke did not appear to affect patient disability at 90 days poststroke, according to findings of the ASSORT* trial presented at the International Stroke Conference 2017 (ISC 2017) in Houston, Texas, US.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!